Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 179-187 , February 2010

C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model

  • Chizuru Sogawa

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • ,
  • Atsushi B. Tsuji

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 206 3429; fax: +81 43 206 0818.
    • ,
  • Hitomi Sudo

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • Department of Pathology and Oncology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
    • ,
  • Aya Sugyo

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • ,
  • Chisato Yoshida

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • Department of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
    • ,
  • Kenichi Odaka

      Affiliations

    • Molecular Probe Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • ,
  • Tomoya Uehara

      Affiliations

    • Department of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
    • ,
  • Yasushi Arano

      Affiliations

    • Department of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
    • ,
  • Mitsuru Koizumi

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • ,
  • Tsuneo Saga

      Affiliations

    • Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan

Received 18 June 2009 ,Revised 28 September 2009 ,Accepted 17 October 2009.

References 

  1. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825
  2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  3. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004;61:2535–2548
  4. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924–2931
  5. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol. 2008;5:102–111
  6. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66:9153–9161
  7. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007;13:5398–5405
  8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  9. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(Suppl 5):S60–S65
  10. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433–438
  11. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–445
  12. Yamamura M, Hirai T, Higashida M, Kubota H, Murakami H, Kawabe Y, et al. A resected case of postoperative liver metastasis of a gastrointestinal stromal tumor showing complete response after imatinib treatment. Gan To Kagaku Ryoho. 2008;35:1945–1949
  13. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235:892–898
  14. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–5058
  15. Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol. 2009;36:379–388
  16. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962;194:495–496
  17. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 1999;59:128–134
  18. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89
  19. Saga T, Sakahara H, Yao Z, Nakamoto Y, Sato N, Hattori N, et al. Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody. Jpn J Cancer Res. 1997;88:1171–1180
  20. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–1136

☆ This research was supported in part by grants from the National Institute of Radiological Sciences and by a Grant-in-Aid for Exploratory Research from Japan Society for the Promotion of Science (No.20659212).

PII: S0969-8051(09)00256-X

doi: 10.1016/j.nucmedbio.2009.10.008

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 179-187 , February 2010

Article Tools

* Image Usage & Resolution